Tvardi Therapeutics Employee Directory
Biotechnology ResearchTexas, United States11-50 Employees
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies that inhibit STAT3, with the aim of treating fibrosis-driven diseases that have significant unmet medical need. STAT3 serves as a central mediator across fibrotic signaling pathways that drive excessive tissue deposition, cell proliferation, survival, and immune suppression, providing rationale for targeting this pathway. The company is evaluating its approach in Phase 2 trials for idiopathic pulmonary fibrosis and hepatocellular carcinoma. Based in Houston, Texas, Tvardi operates as a small biotechnology organization. In 2025, Tvardi announced a merger with Cara Therapeutics, a development described as progressing toward closing in the first half of the year.